Record revenues of $2.8 million in Q1 2021, a 49% increase from the prior year and 13% increase from Q4 2020 Record gross profits (before fair market value.
Record revenues of $2.8 million in Q1 2021, a 49% increase from the prior year and 13% increase from Q4 2020 Record gross profits of $1.1 million, a 171% improvement over Q4 2020 and record. | May 27, 2021
Khiron Life Sciences Reports First Quarter 2021 Financial Results prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Psychopharmacology.
The project, poised to provide patients access to affordable medical cannabis treatment, was launched in 2019 at the Royal College of Psychiatrists in London.
The UK s national medical cannabis registry is monitored by an independent scientific body, Drug Science.
Vertically integrated CPG cannabis company
Khiron Life Sciences Corp. (TSXV:KHRN) (OTCQX:KHRNF) was the first supplier of EU-GMP high-THC dried cannabis flower to Project Twenty 21 s findings. Khiron, which has core operations in Latin America, is a founding member of Project Twenty 21.
Project Twenty 21 s Findings
The findings suggest that patients living with chronic pain, multiple sclerosis, Tourette s syndrome, epilepsy and post-traumatic stress disorder could significantly improve their quality of life by using legally prescribed cannabis.
(1)
Khiron is a founding member of Project Twenty 21 and was the first supplier of EU-GMP high-THC dried cannabis flower to the study
The findings show that medical Cannabis dramatically improves quality of life for people with life-limiting conditions, including Chronic Pain, Multiple Sclerosis, Tourette s Syndrome and PTSD
Legal prescriptions allow patients to access medical cannabis without engaging in criminality and to avoid dependency associated with other medicines commonly prescribed for these debilitating conditions
TORONTO, May 11, 2021 /PRNewswire/ Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF)(Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, applauds the publication today in the accredited scientific journal Psychopharmacology of the first findings arising from Project Twenty 21, UK s first and largest national medical cannabis registry that was launched on November